Drug Profile
SL 701
Alternative Names: Brain cancer vaccine - Stemline Therapeutics; SL-701Latest Information Update: 15 Jun 2020
Price :
$50
*
At a glance
- Originator University of Pittsburgh
- Developer Stemline Therapeutics; University of Pittsburgh
- Class Brain cancer vaccines; Dendritic cell vaccines; Immunotherapies; Peptides; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
- Phase I/II Glioma